Sorted By Test Name - Mayo Medical Laboratories

BTITH
8972
IHDI
82773
Clinical Information: Isoagglutinins are antibodies produced by an individual that cause
agglutination of RBCs in other individuals. People possess isoagglutinins directed toward the A or B
antigen absent from their own RBCs. For example, type B or O individuals will usually possess anti-A.
The anti-A is formed in response to exposure to A-like antigenic structures found in ubiquitous non-red
cell biologic entities (eg, bacteria). Isoagglutinins present in the newborn are passively acquired from
maternal circulation. Such passively acquired isoagglutinins will gradually disappear, and the infant will
begin to produce isoagglutinins at 3 to 6 months of age. Isoagglutinin production may vary in patients
with certain pathologic conditions. Decreased levels of isoagglutinins may be seen in patients with
acquired and congenital hypogammaglobulinemia and agammaglobulinemia. Some individuals with
roundworm infections will have elevated levels of anti-A.
Useful For: Evaluation of individuals with possible hypogammaglobulinemia Investigation of
suspected roundworm infections
Interpretation: The result is reported as antiglobulin phase, in general representing IgG antibody. The
result is the reciprocal of the highest dilution up to 1:2048 at which macroscopic agglutination (1+) is
observed. Dilutions >1:2048 are reported as >2048.
Reference Values:
Interpretation depends on clinical setting.
Clinical References: Technical Manual. 15th edition. Arlington, VA, American Association of
Blood Banks, 2005
Isoagglutinin Titer, Anti-B, Serum
Clinical Information: Isoagglutinins are antibodies produced by an individual that cause
agglutination of red blood cells in other individuals. People possess isoagglutinins directed toward the A
or B antigen absent from their own RBCs. For example, type A or O individuals will usually possess
anti-B. The anti-B is formed in response to exposure to B-like antigenic structures found in ubiquitous
non-red cell biologic entities (eg, bacteria). Isoagglutinins present in the newborn are passively acquired
from maternal circulation. Such passively acquired isoagglutinins will gradually disappear, and the infant
will begin to produce isoagglutinins at 3 to 6 months of age. Isoagglutinin production may vary in patients
with certain pathologic conditions. Decreased levels of isoagglutinins may be associated with acquired
and congenital hypogammaglobulinemia and agammaglobulinemia.
Useful For: Evaluation of individuals with possible hypogammaglobulinemia Investigation of
suspected roundworm infections
Interpretation: The result is reported as antiglobulin phase, in general representing IgG antibody. The
result is the reciprocal of the highest dilution up to 1:2048 at which macroscopic agglutination (1+) is
observed. Dilutions >1:2048 are reported as >2048.
Reference Values:
Interpretation depends on clinical setting.
Clinical References: Technical Manual. 15th edition. Arlington, VA, American Association of
Blood Banks, 2005
Isocyanate HDI, IgE
Clinical Information: Clinical manifestations of immediate hypersensitivity (allergic) diseases are
caused by the release of proinflammatory mediators (histamine, leukotrienes, and prostaglandins) from
immunoglobulin E (IgE)-sensitized effector cells (mast cells and basophils) when cell-bound IgE
antibodies interact with allergen. In vitro serum testing for IgE antibodies provides an indication of the
immune response to allergen(s) that may be associated with allergic disease. The allergens chosen for
testing often depend upon the age of the patient, history of allergen exposure, season of the year, and
clinical manifestations. In individuals predisposed to develop allergic disease(s), the sequence of
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1052